LSTA — Lisata Therapeutics, Inc.
$1.06+6.44%
Last close: · regular session
Last 60 sessions
LSTA closed at $1.06 (+6.44%) on Oct 26, 2026. Float: 7.4M shares. Latest SEC filing: ARS on Oct 19, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for LSTA in the TickerWise workspace.
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 26
- Website: https://www.lisata.com
Latest SEC filings for LSTA
Latest LSTA news
- Lisata Therapeutics wins new US patent for pancreatic cancer drug Read article
- Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors Read article
- Lisata subsidiary Marea treats first patient in MAR002 acromegaly trial Read article
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly Read article
- Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders Read article
- EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- LSTA, FSHP, BWIN, and ACVA Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.